Abstract
Glucagon-like peptide-1 (GLP-1) is a hormone released by intestinal cells into the circulation in response to food intake. It has specific β-cell receptors that induces cyclic adenosine monophosphate (cAMP) production and cAMP-dependent protein kinase activation. Desensitization of the GLP-1 receptor on β-cells is proposed as a factor contributing to the pathogenesis of noninsulin-dependent diabetes mellitus (NIDDM), and its agonists as new potential NIDDM therapeutic agents. At pharmacological doses, GLP-1 infusion can improve postprandial insulin response in NIDDM patients. As it induces both insulin secretion and production, and mainly glucose-dependent activation, GLP-1 has a unique advantage over sulfonyl urea drugs in NIDDM treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 690-695 |
| Number of pages | 6 |
| Journal | Israel Journal of Medical Sciences |
| Volume | 33 |
| Issue number | 10 |
| State | Published - Oct 1997 |
| Externally published | Yes |
Keywords
- Cyclic AMP
- Diabetes mellitus
- GTP-binding protein
- Glucagon-like peptide 1
- Incretin hormone
- Insulin
